Crossmark

The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study

Crossref DOI link: https://doi.org/10.1016/j.jcjd.2017.01.007

Published Print: 2018-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aronson, Ronnie

Goldenberg, Ronald

Boras, Damir

Skovgaard, Rasmus

Bajaj, Harpreet
Funding

Funding for this research was provided by:

Eli Lilly and Company

Janssen Pharmaceuticals

Roche

Pfizer

Valeant Pharmaceuticals International

Sanofi

AstraZeneca

Takeda Canada

Medtronic

GlaxoSmithKline

Novo Nordisk

Bristol-Myers Squibb Canada

Abbott Laboratories

Boehringer Ingelheim

Novartis

Merck
License Information

Text and Data Mining valid from 2018-02-01

Text and Data Mining valid from 2018-02-01

Version of Record valid from 2017-01-25
More Information

This article is maintained by: Elsevier

Article Title: The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study

Journal Title: Canadian Journal of Diabetes

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jcjd.2017.01.007

Content Type: article

Copyright: © 2017 The Author(s). Published on behalf of the Canadian Diabetes Association.